Browsing by Author "FitzGerald, JM"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    GINA 2019: a fundamental change in asthma management
    Reddel, HK; FitzGerald, JM; Bateman, ED; Bacharier, LB; Becker, A; Brusselle, G; Buhl, R; Cruz, AA; Fleming, L; Inoue, H; Ko, FWS; Krishnan, JA; Levy, ML; Lin, JT; Pedersen, SE; Sheikh, A; Yorgancioglu, A; Boulet, LP
  • No Thumbnail Available
    Item
    Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
    Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. (C) 2021 by the American Thoracic Society. Reprinted with permission.
  • No Thumbnail Available
    Item
    Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key Changes
    Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
  • No Thumbnail Available
    Item
    Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key Changes
    Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
  • No Thumbnail Available
    Item
    Global initiative for Asthma Strategy 2021: executive summary and rationale for key changes
    Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g. medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not he treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
  • No Thumbnail Available
    Item
    Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes
    Reddel, HK; Bacharier, LB; Bateman, ED; Brightling, CE; Brusselle, GG; Buhl, R; Cruz, AA; Duijts, L; Drazen, JM; FitzGerald, JM; Fleming, LJ; Inoue, H; Ko, FW; Krishnan, JA; Levy, ML; Lin, JT; Mortimer, K; Pitrez, PM; Sheikh, A; Yorgancioglu, AA; Boulet, LP
    The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by >= 60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta(2)-agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes. (C) 2022 . by the American Thoracic Society, which grants unconditional and unlimited licenses to the European Respiratory Journal, Respirology, Archivos de Bronconeumologia, and Journal of Allergy and Clinical Immunology: In Practice.